跳至主要内容
临床试验/NCT00144560
NCT00144560已完成不适用

An Open-Label, Clinical Pharmacology Study to Investigate Drug-Drug Interaction in Patients With RA

Chugai Pharmaceutical0 个研究点目标入组 31 人开始时间: 2005年2月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
31
主要终点
20% improvement based on the ACR criteria compared with the baseline value.

研究概览

简要总结

This is an open-label, clinical pharmacology study to investigate drug-drug interaction in patients with RA.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients who are diagnosed with RA according to the 1987 American College of Rheumatology (ACR) classification criteria
  • •Patients who contracted RA at least 6 months prior

排除标准

  • •Patients with Class IV Steinbrocker functional impairment at enrollment.
  • •Patients who have been treated for the underlying disease with a biological agent, such as infliximab or etanercept and have been receiving treatment with leflunomide, within 12 weeks before initiation of treatment with the probe drug

研究组 & 干预措施

未命名试验

干预措施: MRA(Tocilizumab) (Drug)

结局指标

主要结局

20% improvement based on the ACR criteria compared with the baseline value.

时间窗: throughout study

次要结局

  • Time courses taken from baseline values for DAS28, for ACR20%, 50%, and 70% improvement, and for each ACR core set variable.(Week 0,Week 1, Week 2)

研究者

申办方类型
Industry

相似试验